ClinicalTrials.gg
CompletedNCT03911713Updated Jan 25, 2022Results posted

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

A Phase 2 interventional study of VX-561 and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 48 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-25.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
77
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 84 studies testing ivacaftor in Cystic Fibrosis — 4 open to participants now, 7 under way, 2 of them phase 3. ivacaftor · Cystic Fibrosis.

Enrollment
38th of 84
77 · median 70
Started
2019
with 2 others
Phase 2
17 of 84
none open now
Registered
62nd of 84
by date
Lead sponsor
74 of 84
Vertex Pharmaceuticals Incorporated

Among the 84 studies testing ivacaftor in Cystic Fibrosis, this one is the 38th largest by enrollment, is one of 3 that started in 2019, is one of 17 in phase 2, and was the 62nd registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

4 of the 84 studies testing ivacaftor in Cystic Fibrosis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About ivacaftor

ivacaftor: first FDA approval 2012 (KALYDECO), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing ivacaftor in Cystic Fibrosis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety, pharmacodynamic (PD) and pharmacokinetic (PK) effect of VX-561.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Must have 1 of the following 9 CFTR mutations on at least 1 allele: G551D, G178R, S549N, S549R, G551S, G1244E, S1251N, S1255P, or G1349D
  • On ivacaftor therapy
  • value ≥40% and ≤100% of predicted mean for age, sex, and height

Key Exclusion Criteria:

  • History of cirrhosis with or without portal hypertension
  • History of solid organ or hematological transplantation
  • Lung infection with organisms associated with a more rapid decline in pulmonary status

Other protocol defined Inclusion/Exclusion criteria may apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
77 participants (actual)

Study arms

  • Active comparator
    Ivacaftor

    Participants received IVA 150 milligrams (mg) orally every 12 hours (q12h) in the treatment period for 12 weeks.

    Drug: IVA · Drug: Placebo

  • Experimental
    VX-561: 25 mg

    Participants received VX-561 25 mg orally daily (qd) in the treatment period for 12 weeks.

    Drug: VX-561 · Drug: Placebo

  • Experimental
    VX-561: 50 mg

    Participants received VX-561 50 mg orally qd in the treatment period for 12 weeks.

    Drug: VX-561 · Drug: Placebo

  • Experimental
    VX-561: 150 mg

    Participants received VX-561 150 mg orally qd in the treatment period for 12 weeks.

    Drug: VX-561 · Drug: Placebo

  • Experimental
    VX-561: 250 mg

    Participants received VX-561 250 mg orally qd in the treatment period for 12 weeks.

    Drug: VX-561 · Drug: Placebo

Interventions

  • DrugVX-561

    VX-561 tablets for oral administration.

    Also known as: CTP-656, Deutivacaftor (D-IVA)

  • DrugIVA

    150-mg film-coated tablet for oral administration.

    Also known as: VX-770, Ivacaftor

  • DrugPlacebo

    Placebo matched to IVA.

  • DrugPlacebo

    Placebos matched to VX-561.

06

What researchers measure

Primary outcomes

  1. Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

    FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

    Time frame: From Baseline at Week 12

Secondary outcomes

  1. Absolute Change in Sweat Chloride (SwCl)

    Sweat samples were collected using an approved collection device.

    Time frame: From Baseline at Week 12

  2. Observed Pre-Dose Concentration (Ctrough) of VX-561 and Its Metabolites (M1-VX-561 and M6-VX-561) and IVA and Its Metabolites (M1-IVA and M6-IVA)

    Time frame: At Week 4

  3. Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to Week 16

07

Results

Posted Jan 25, 2022

Participant flow

Participant flow — Overall Study
MilestoneIvacaftorVX-561: 25 mgVX-561: 50 mgVX-561: 150 mgVX-561: 250 mg
Started126112424
Full analysis set116112324
Completed114112224
Not completed12020
Withdrew: Lost to follow-up02000
Withdrew: Other00010
Withdrew: Randomized, never dosed10010

Outcome measures

PrimaryAbsolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)

FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration.

Time frame:
From Baseline at Week 12
Reported as:
Least squares mean · percentage points
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
percentage pointsIvacaftorVX-561: 150 mgVX-561: 250 mg
Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)-0.8 (-6.2 to 4.7)3.1 (-0.8 to 7.0)2.7 (-1.0 to 6.5)
SecondaryAbsolute Change in Sweat Chloride (SwCl)

Sweat samples were collected using an approved collection device.

Time frame:
From Baseline at Week 12
Reported as:
Least squares mean · millimole per liter (mmol/L)
Absolute Change in Sweat Chloride (SwCl)
millimole per liter (mmol/L)IvacaftorVX-561: 150 mgVX-561: 250 mg
Absolute Change in Sweat Chloride (SwCl)0.9 (-9.5 to 11.3)3.3 (-4.6 to 11.2)-6.5 (-14.1 to 1.2)
SecondaryObserved Pre-Dose Concentration (Ctrough) of VX-561 and Its Metabolites (M1-VX-561 and M6-VX-561) and IVA and Its Metabolites (M1-IVA and M6-IVA)
Time frame:
At Week 4
Reported as:
Mean · nanogram per milliliter (ng/mL)
Observed Pre-Dose Concentration (Ctrough) of VX-561 and Its Metabolites (M1-VX-561 and M6-VX-561) and IVA and Its Metabolites (M1-IVA and M6-IVA)
nanogram per milliliter (ng/mL)IvacaftorVX-561: 25 mgVX-561: 50 mgVX-561: 150 mgVX-561: 250 mg
VX-561: Week 4—26.1 ± 24.7123 ± 61.6458 ± 2731100 ± 856
M1-VX-561: Week 4—18.1 ± 17.7108 ± 58.6378 ± 213739 ± 407
M6-VX-561: Week 4—NA ± NA59.8 ± 34.0211 ± 189370 ± 233
IVA: Week 4952 ± 766————
M1-IVA: Week 41330 ± 774————
M6-IVA: Week 4662 ± 398————
SecondarySafety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame:
Baseline up to Week 16
Reported as:
Number · participants
Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
participantsIvacaftorVX-561: 25 mgVX-561: 50 mgVX-561: 150 mgVX-561: 250 mg
Participants with AEs8482123
Participants with SAEs12221

Adverse events

Collected over Baseline up to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ivacaftor0/11 (0%)1/11 (9.1%)8/11 (72.7%)
VX-561: 25 mg0/6 (0%)2/6 (33.3%)4/6 (66.7%)
VX-561: 50 mg0/11 (0%)2/11 (18.2%)8/11 (72.7%)
VX-561: 150 mg0/23 (0%)2/23 (8.7%)17/23 (73.9%)
VX-561: 250 mg0/24 (0%)1/24 (4.2%)20/24 (83.3%)
Most frequent serious events
Most frequent serious events
EventIvacaftorVX-561: 25 mgVX-561: 50 mgVX-561: 150 mgVX-561: 250 mg
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations1/111/62/112/231/24
Distal intestinal obstruction syndromeGastrointestinal disorders0/111/60/110/230/24
Forced expiratory volume decreasedInvestigations0/111/60/110/230/24
Most frequent other events
Showing 10 of 63
Most frequent other events
EventIvacaftorVX-561: 25 mgVX-561: 50 mgVX-561: 150 mgVX-561: 250 mg
DyspnoeaRespiratory, thoracic and mediastinal disorders0/112/60/112/230/24
CoughRespiratory, thoracic and mediastinal disorders2/111/61/116/231/24
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations2/110/62/112/234/24
NasopharyngitisInfections and infestations2/110/60/110/233/24
Aspartate aminotransferase increasedInvestigations0/111/62/111/231/24
Blood creatine phosphokinase increasedInvestigations1/110/62/110/231/24
Nasal congestionRespiratory, thoracic and mediastinal disorders2/111/61/112/231/24
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/110/60/114/230/24
Respiration abnormalRespiratory, thoracic and mediastinal disorders2/110/61/114/230/24
Sputum increasedRespiratory, thoracic and mediastinal disorders0/110/61/114/233/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)IvacaftorVX-561: 25 mgVX-561: 50 mgVX-561: 150 mgVX-561: 250 mgTotal
Mean33.3 ± 11.733.0 ± 10.627.8 ± 9.032.5 ± 8.537.4 ± 11.433.5 ± 10.4
Sex: Female, Male
Sex: Female, Male(Participants)IvacaftorVX-561: 25 mgVX-561: 50 mgVX-561: 150 mgVX-561: 250 mgTotal
Female4238926
Male748151549
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IvacaftorVX-561: 25 mgVX-561: 50 mgVX-561: 150 mgVX-561: 250 mgTotal
Hispanic or Latino001102
Not Hispanic or Latino11610222473
Unknown or Not Reported000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IvacaftorVX-561: 25 mgVX-561: 50 mgVX-561: 150 mgVX-561: 250 mgTotal
American Indian or Alaska Native000000
Asian100001
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White10611232474
More than one race000000
Unknown or Not Reported000000
Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)(percentage points)IvacaftorVX-561: 25 mgVX-561: 50 mgVX-561: 150 mgVX-561: 250 mgTotal
Mean74.0 ± 21.263.6 ± 22.466.8 ± 17.472.6 ± 17.373.9 ± 17.071.6 ± 18.0
08

Study locations

48 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Banner University of Arizona Medical Center
    Tucson, Arizona 85724, United States
  • Miller Children's Hospital / Long Beach Memorial
    Long Beach, California 90806, United States
  • UCSF Gateway Medical Center
    San Francisco, California 94143, United States
  • National Jewish Health
    Denver, Colorado 80206, United States
  • University of Miami Miller School of Medicine
    Miami, Florida 33136, United States
  • Central Florida Pulmonary Group, PA
    Orlando, Florida 32803, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Massachusetts General Hospital Cystic Fibrosis Center Clinical Research Center
    Boston, Massachusetts 02114, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Michigan Medicine
    Ann Arbor, Michigan 48109-5212, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Cardinal Glennon Children's Hospital
    Saint Louis, Missouri 63104, United States
  • Washington University School of Medicine / St. Louis Children's Hospital
    Saint Louis, Missouri 63110, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • University of North Carolina Hospitals
    Chapel Hill, North Carolina 27514, United States
  • UC Health Holmes
    Cincinnati, Ohio 45220, United States
  • ProMedica Toledo Hospital/Toledo Children's Hospital/Pediatric Pulmonary & Cystic Fibrosis Center
    Toledo, Ohio 43606, United States
  • University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma 73104, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
  • Dell Children's Medical Group
    Austin, Texas 78723, United States
  • The University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • University of Utah / Primary Children's Medical Center
    Salt Lake City, Utah 84132, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53792, United States
  • The Prince Charles Hospital
    Chermside, Australia
  • Alfred Hospital
    Melbourne, VIC, Australia
  • Mater Adult Hospital
    South Brisbane, Australia
  • Westmead Hospital
    Westmead, Australia
  • Universitair Ziekenhuis Gent
    Gent, Belgium
  • Friedrich-Alexander University of Erlangen-Nuremberg, University Children's Hospital
    Erlangen, Germany
  • Ruhrlandklinik Westdeutsches Lungenzentrum am Klinikum Essen
    Essen, Germany
  • Universitätsklinikum Halle (Saale) / Universitätsklinik und Poliklinik für Innere Medizin, Schwerpunkt Pneumologie
    Halle, Germany
  • Pneumologisches Studienzentrum Muenchen-West
    Muenchen, Germany
  • University Hospital Wuerzburg
    Würzburg, Germany
  • Cork University Hospital
    Dublin 12, Ireland
  • Beaumont Hospital
    Dublin 9, Ireland
  • St. Vincent's University Hospital
    Dublin, Ireland
  • University Hospital Limerick (Adults)
    Limerick, Ireland
  • UMC St. Radboud
    Nijmegen, Netherlands
  • Clinical Research Facility, Queen Elizabeth University Hospital
    Glasgow, United Kingdom
  • St. James University Hospital
    Leeds, United Kingdom
  • Liverpool Heart and Chest Hospital
    Liverpool, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Aug 2020, 16 months.

Results were first posted in Jan 2022, 1 year 5 months after primary completion. A results delay was requested in Aug 2021.

Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's 16 months is close to that.

Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2019
First posted
Apr 11, 2019
StartActual
Apr 17, 2019
Primary completionActual
Aug 20, 2020
CompletionActual
Aug 20, 2020
Results delay requested
Aug 19, 2021
Results first posted
Jan 25, 2022
Last update
Jan 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03911713
Responsible party
Sponsor
First posted
Apr 11, 2019
Start date
Apr 17, 2019
Primary completion
Aug 20, 2020
Completion
Aug 20, 2020
Results posted
Jan 25, 2022
Last update
Jan 25, 2022

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivacaftor

Start the discussion